PGC-1α, a transcription factor coactivator, is recognized as a target for lowering the risk of IR and metabolic syndrome due to mitochondrial dysfunction (Williams and Gurd, 2012; Singh et al., 2020). This evidence concerns the gene PPARGC1A and metabolic syndrome.